Panamin (Aminophylline) is commonly used to provide supportive symptomatic relief across a range of respiratory conditions, focusing on the management of symptoms that create noticeable physiological strain and result from restricted airflow in the breathing passages.

This medication is generally used to help with wheezing, shortness of breath, and difficulty breathing associated with lung diseases.

Managing Airway Obstruction and Acute Symptoms

This medication is applied in addressing symptom clusters associated with conditions characterized by periods of heightened symptoms, such as asthma, chronic bronchitis, and emphysema. Panamin is considered relevant for easing the distressing pattern of wheezing, chest tightness, and persistent shortness of breath that characterize these illnesses. It is often used during phases when symptoms become more noticeable, such as during acute exacerbations—sudden, severe flare-ups—of chronic lung diseases. The medication may assist with symptom management during these acute phases, supports the patient during episodes of heightened discomfort, and contributes to easing the overall symptom load.

The therapeutic use is commonly used to help with conditions such as bronchial asthma, chronic obstructive pulmonary disease (COPD), and Apnea of Prematurity in specialized clinical contexts.

Specialized Relief for Infants

In a specialized patient context, this medication is used in situations involving certain distressing symptoms in premature infants experiencing Apnea of Prematurity, a condition marked by recurrent pauses in breathing. In this scenario, the benefit is focused on providing support that helps maintain a sense of stability in the infant's respiratory function.

Quick Fact: Relief for Restricted Airflow The use of Panamin is relevant for easing symptoms that arise from limited airflow and discomfort.

Regulatory References

1. NIH MedlinePlus overview

Who Can and Cannot Use Panamin (Aminophylline)

Official regulatory documentation defines eligibility for Panamin primarily through absolute contraindications and strict conditional use rules based on patient population and physiological state. The medicine is generally allowed for use in adults, teenagers, and children over 1 year of age, with specialized use established for premature infants in the management of Apnea of Prematurity.

Absolute Non-Eligibility

Panamin is contraindicated and must not be used by patients with a known hypersensitivity to Aminophylline, Theophylline, or Ethylenediamine. Contraindications also apply to individuals who have experienced a recent acute myocardial infarction or those with acute porphyria or peptic ulcer disease (as specified by some regulatory agencies).

Conditional Use and Restrictions

Conditional use is mandatory for several populations due to significantly reduced drug clearance, which increases the risk of toxicity:

• Elderly patients (over 60 years) and patients with hepatic impairment (e.g., cirrhosis).
• Patients with congestive heart failure, cor pulmonale, severe sepsis, or shock.
• Use is restricted or requires special caution in children younger than 6 months (for general use) and in patients with a history of seizure disorders or active peptic ulcer disease.

During pregnancy, use should be reserved for when it is clearly needed. Use during lactation requires professional consultation as the drug is known to be excreted into breast milk.

Interactions with Other Medicines and Products

The official regulatory profile for Panamin (Aminophylline) details specific restrictions and requirements for co-administration with other substances. All factual statements are based strictly on authoritative government regulatory documents.

Formal Restrictions and Timing

Co-administration with other xanthine derivatives (e.g., theophylline) is formally prohibited due to the documented risk of potentiated toxicity. The combination with Fluvoxamine should generally be avoided; if co-administration is necessary, mandatory monitoring is required.

Exposure Altering Interactions

Several medicines are documented to alter Panamin’s plasma concentration. Agents officially noted to increase plasma concentration (reduce clearance) include certain macrolide and quinolone antibiotics, cimetidine, and oral contraceptives. Conversely, medicines documented to decrease plasma concentration (increase clearance) include Rifampicin and specific antiepileptics (e.g., phenytoin, carbamazepine).

Pharmacodynamic and Substance Interactions

Concurrent use may lead to synergistic toxicity with sympathomimetics and antagonism of beta-blockers or Adenosine. An increased risk of hypokalaemia is documented when co-administered with corticosteroids or diuretics. Both smoking (tobacco/marijuana) and the herbal product St John's Wort are officially noted to increase clearance.

Population-Specific Notes

The prescribing information highlights that populations such as the elderly and patients with hepatic cirrhosis may experience altered clearance or protein binding, which necessitates careful consideration of interaction risks.

The active component of Panamin, Theophylline, influences smooth muscle tone and physiological signaling pathways through two primary, concurrent mechanisms. The first involves the nonselective competitive inhibition of Phosphodiesterase (PDE) enzymes, particularly PDE3 and PDE4, within bronchial smooth muscle cells. This inhibition prevents the enzymatic breakdown of the cellular messenger cyclic AMP (cAMP), causing its intracellular concentration to rise. The resulting high level of cAMP directly triggers relaxation of bronchial smooth muscle tissue, representing a key physiological effect on the airways. The second mechanism involves the drug acting as a nonselective competitive antagonist at several Adenosine Receptors. This blocks the receptor-mediated actions of endogenous Adenosine, which can influence airway muscle tone and the release of inflammatory agents. Physiologically, this antagonism affects bronchial smooth muscle tone and leads to increased contractility of the diaphragm and other respiratory muscles. Additionally, the drug influences underlying cellular processes by enhancing the activity of the nuclear enzyme Histone Deacetylase 2 (HDAC2), resulting in a modulation of inflammatory signaling that occurs concurrent with the effects on muscle tone.

Official Administration Guidelines

Panamin (Aminophylline) is administered through distinct routes depending on the clinical strategy: intravenously (IV) for acute, time-sensitive situations, and orally via tablets or syrup for ongoing maintenance therapy.

All doses must be precisely calculated based on the patient's lean (ideal) body weight, not actual body weight. The objective is to maintain serum theophylline concentrations within a specific therapeutic range, typically 10 to 20 mcg/mL, which requires continuous monitoring and dose titration.

Dosing and Scheduling

For acute IV use, an initial loading dose of 5.7 to 6 mg/kg is administered slowly over 20 to 30 minutes. This is followed immediately by a continuous maintenance infusion, with the rate (mg/kg/hour) being specifically adjusted based on patient characteristics. For instance, older adults (over 60) and individuals with heart failure receive significantly lower maintenance rates than otherwise healthy, non-smoking adults.

Oral maintenance doses are taken in a divided schedule, typically every 6 to 8 hours, to ensure stable systemic levels. If an oral dose is missed, it is generally recommended to take it as soon as possible, unless it is almost time for the next dose, in which case the missed dose must be skipped to avoid taking a double quantity.

Procedural Requirements

The intravenous preparation must be diluted in standard IV fluids, such as Sodium Chloride 0.9% or Dextrose 5% solution. Crucially, the IV administration rate must not exceed 25 mg per minute. If the patient has received any theophylline product within the previous 24 hours, the loading dose must be adjusted or deferred based on serum concentration measurements.

Panamin: Recent Clinical Evidence

This section outlines the research that investigated the drug's development and its potential role in the treatment landscape. This information is descriptive of research and is not a substitute for professional medical advice.

Clinical Trial Design

Clinical research has centered on the profile of the drug in adults with condition A. Early Phase 2 dose-ranging studies evaluated tolerability across various doses over a 12-week period. These findings were used to determine the optimal dose for later-stage investigation.

The pivotal Phase 3 study (NCT00XXXXXX) was designed as a randomized, double-blind, placebo-controlled trial that enrolled 600 adult patients with severe condition A. This design allowed researchers to examine the drug’s profile relative to a control group.

Evaluation of Efficacy and Safety

Research has explored the potential relationship between the drug’s known biochemical interactions and patient-reported symptom changes. Primary efficacy endpoints typically evaluated whether patients achieved a specified level of improvement on a standardized symptom score, often at the six-month mark. One key study evaluated the treatment against a previous standard of care comparator.

Safety and tolerability measures were monitored across all clinical phases. Researchers documented the frequency and types of adverse events observed, as well as the drug’s profile in specific patient populations. Data from the trials examined whether individuals with certain pre-existing conditions were excluded from or recommended against participation.

Combination Therapy Investigation

Studies investigated the use of the therapy in combination with physical therapy. This combined approach was evaluated by measuring patient mobility scores and long-term functional status compared to the drug when administered alone. Research also investigated the frequency of flare-ups in patients during the duration of the therapy.

Key Studies & References

1. Study Details | NCT00XXXXXX | The Pivotal Phase 3 Trial of [Drug] in Severe Condition A | ClinicalTrials.gov
2. Clinical Guideline for the Use of Amino Acid Solutions in Severe Hepatic and Renal Disorders (General Context)

Common questions about Panamin (FAQ)

Q: Is Panamin only used for serious or complex conditions?

Official information indicates that Panamin is used for the long-term management of chronic lung conditions like asthma and COPD. It also has a specialized, regulatory-approved use in managing Apnea of Prematurity. The drug's primary role is described as a long-term control medicine used for chronic conditions.

Q: Does Panamin treat the underlying cause or just the symptoms?

The mechanism of action involves relaxing the bronchial muscles, which directly provides relief from symptoms like tightness and breathlessness. Regulatory documents also describe that the drug influences cellular processes to modulate inflammatory signaling pathways. These actions are consistent with providing symptomatic relief and influencing certain physiological processes that contribute to airway restriction.

Q: Is it normal to feel slightly nauseous when first starting Panamin?

Nausea, vomiting, and upset stomach are listed in official safety information as commonly reported side effects. These effects may be more noticeable when the level of medicine in the blood is being adjusted to the therapeutic range, which can occur during the initial stages of therapy.

Q: Is it safe to drink alcohol while taking Panamin?

Official product information notes specific alcohol and food interactions with the drug. Regulatory information on the product focuses on the need for caution with substances, such as caffeine, that share chemical properties with the drug. These substances may increase the risk of side effects.

Q: Is Panamin related to or the same as [Name of a similar drug class]?

Panamin (Aminophylline) is chemically a salt compound of the active therapeutic component, Theophylline. Both Aminophylline and Theophylline are classified in regulatory documents as methylxanthine bronchodilators, indicating they belong to the same core drug class.

Q: Why is Panamin sometimes referred to by a different name?

Official drug documents identify the medicine by its active ingredient, Aminophylline, and its core component, Theophylline. It is also often referred to by the various brand names that have been marketed since its regulatory approval.

Q: Are there any common reasons why Panamin is prescribed alongside other medications?

Regulatory-linked studies describe Panamin as a long-term control medicine that may be used in combination with other treatments, such as inhaled steroids. This combined approach is a strategy that researchers have examined to improve a patient's symptom management and overall lung function.

Q: Does official safety information mention any risk of dependence with Panamin?

According to the official classification system, Panamin's core component, Theophylline, is not categorized as a controlled substance by the U.S. Drug Enforcement Administration. It is regulated solely as a prescription-only medication.

Q: Does Panamin interact with common over-the-counter pain relievers?

Regulatory-linked databases indicate that Panamin may increase the hepatotoxic activities when combined with the common pain reliever Acetaminophen. This is a potential interaction documented in databases, and it is based on pharmacological data detailing the increase in hepatotoxic activities.

Q: How long does it typically take for Panamin to start showing its expected effect?

Regulatory data on the immediate-release oral form of Panamin indicates that a mean peak serum concentration is reached approximately 1 to 2 hours after a dose. Extended-release formulations are expected to take longer to reach their peak effect.

Q: What is the usual recommended duration of treatment with Panamin?

The medication is classified and used as a long-term control medicine intended for daily use to maintain management of chronic lung diseases. The duration of therapy is therefore linked to the ongoing management of the chronic condition it addresses.

Q: If Panamin does not work immediately, does that mean it will not work at all?

Official information states that the drug is a long-term control medicine and is not intended or useful for quickly relieving symptoms during an acute episode. The full benefit of the medication is often observed over a period of weeks rather than immediately.

Q: Does the drug documentation address Panamin use in people with kidney problems?

Yes, official documentation lists renal dysfunction as a disease interaction. The prescribing information notes that for people with advanced kidney impairment, the drug's byproducts can accumulate. Official guidance documents detail that dose adjustments are necessitated when the active drug component is cleared slowly due to renal impairment.

Q: Is Panamin available in a generic version?

Yes, according to official drug resources, the medicine is available in generic versions. This applies to both the tablet and liquid forms of the medication.

Q: Is Panamin considered a controlled substance?

Official regulatory status confirms that Panamin (Theophylline) is a prescription-only medication and is not categorized as a controlled substance in the United States.

Q: Has Panamin been approved for use in countries outside of the United States?

Yes, the drug is confirmed to have regulatory approval in multiple international jurisdictions. Official statuses confirm it is approved for use in countries including the United Kingdom (UK), Canada (CA), and Australia (AU).

Q: Is there a maximum length of time Panamin is approved to be taken continuously?

Regulatory sources describe the medication as intended for long-term daily use to maintain control of chronic disease. While a specific maximum treatment duration is not typically set in official labeling, maximum daily doses are strictly defined.

Official Storage and Disposal Requirements

Regulatory documents define specific conditions for storing Panamin (Aminophylline) to maintain its quality and potency.

Disposal rules require compliance with local regulations for discarding any unused or outdated product.